Flumazenil is indicated for reversal of sedation from benzodiazepines 
administered during therapeutic or diagnostic procedures and during induction or 
maintenance of general anesthesia, as well as for benzodiazepine overdose. Bolus 
doses of flumazenil are usually adequate to achieve reversal; however, when 
medical conditions may lead to a prolonged half-life of the benzodiazepine 
involved, continuous infusion may be warranted. A 67-year-old man with 
chlordiazepoxide toxicity required a 9-day infusion of flumazenil to prevent 
resedation and respiratory insufficiency; he initially was admitted to the 
hospital for alcohol detoxification. Concomitant medical conditions and the 
metabolism characteristics of each benzodiazepine must dictate the agent of 
choice. When measures are required to ensure adequate recovery of a patient's 
respiratory function and mental awareness, such as in patients with 
benzodiazepine toxicity, consideration of continuous-infusion flumazenil is 
warranted.